Active Ingredient History

NOW
  • Now
Levetiracetam is an anticonvulsant medication used to treat epilepsy. Levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of seizure activity. The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only minimal activity in submaximal stimulation and in threshold tests. Levetiracetam also displayed inhibitory properties in the kindling model in rats, another model of human complex partial seizures, both during kindling development and in the fully kindled state. The predictive value of these animal models for specific types of human epilepsy is uncertain. In vitro and in vivo recordings of epileptiform activity from the hippocampus have shown that levetiracetam inhibits burst firing without affecting normal neuronal excitability, suggesting that levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of seizure activity. Levetiracetam at concentrations of up to 10 µM did not demonstrate binding affinity for a variety of known receptors, such as those associated with benzodiazepines, GABA (gamma-aminobutyric acid), glycine, NMDA (Nmethyl-D-aspartate), re-uptake sites, and second messenger systems. Furthermore, in vitro studies have failed to find an effect of levetiracetam on neuronal voltage-gated sodium or T-type calcium currents and levetiracetam does not appear to directly facilitate GABAergic neurotransmission. However, in vitro studies have demonstrated that levetiracetam opposes the activity of negative modulators of GABA- and glycine-gated currents and partially inhibits N-type calcium currents in neuronal cells. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug. Levetiracetam, along with other anti-epileptic drugs, can increase the risk of suicide behavior or thoughts. People taking levetiracetam should be monitored closely for signs of worsening depression, suicidal thoughts or tendencies, or any altered emotional or behavioral states.   NCATS

  • SMILES: CC[C@H](N1C[C@@H](CC1=O)C=C(F)F)C(=O)N
  • InChIKey: ANWPENAPCIFDSZ-RQJHMYQMSA-N
  • Mol. Mass: 232.23
  • ALogP: 0.88
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$0.0337 - $97.2580

Australia

$0.1490 - $48.3477
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

(2s)-2-((4s)-4-(2,2-difluoroethenyl)-2-oxopyrrolidin-1-yl)butanamide | alpha-ethyl-2-oxo-1-pyrrolidineacetamide | desitrend | etiracetam | etiracetam, r-isomer | etiracetam, s-isomer | keppra | keppra xr | levetiracetam | (-)-levetiracetam | levetiracetame | levetiracetam in sodium chloride | levetiracetamum | levitiracetam | levroxa | matever | seletracetam | ucb-22059 | ucb-44212 | ucb 6474 | ucb-6474 | ucb brand of levetiracetam | ucb l059 | ucb-l059 | ucb l060 | ucb-l060

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue